Pathogenetic aspects of responsiveness to ordansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome – a preliminary study - Hrycaj, P; Stratz, T; Mennet, P; Muller, W (J Rheumatol, 1996)